Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 10/20 | 0.75 |
| ▸ | NPY1R | P25929 | 10/20 | 0.75 |
| ▸ | NPY4R | P50391 | 8/20 | 0.75 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.75 |
| ▸ | TFPI | P10646 | 5/20 | 0.72 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.68 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.67 |
| ▸ | CALCR | P30988 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15669203 | 0.97 | NPY2R (0.74) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL15669269 | 0.94 | NPY2R (0.76) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30574247 | 0.93 | NPY2R (0.74) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL4329513 | 0.93 | VIPR1 (0.78) | NPY2RNPY1RNPY4RNPY5RVIPR1 | |
| SCHEMBL238214 | 0.91 | NPY2R (0.69) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30574250 | 0.90 | NPY2R (0.72) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30735721 | 0.90 | NPY2R (0.77) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL29436010 | 0.90 | NPY2R (0.77) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30433571 | 0.90 | NPY2R (0.69) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL29399759 | 0.90 | NPY2R (0.89) | NPY2RNPY1RNPY4RNPY5RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238382-A1 | URI Agonist/Vasodilator | LILLY CO ELI (US) | 2024-07-18 | — | — | US | disclosed |
| US-11872266-B2 | Rapid-acting insulin compositions | ELI LILLY AND COMPANY (US) | 2024-01-16 | — | — | US | disclosed |
| CN-110662551-B | Quick acting insulin compositions | 伊莱利利公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4169505-A1 | RAPID-ACTING INSULIN COMPOSITIONS | Eli Lilly and Company (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4108253-A1 | RAPID-ACTING INSULIN COMPOSITIONS | Eli Lilly and Company (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3233108-B1 | RAPID-ACTING INSULIN COMPOSITIONS | LILLY CO ELI (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220072105-A1 | RAPID-ACTING INSULIN COMPOSITIONS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| EP-3943155-A1 | RAPID-ACTING INSULIN COMPOSITIONS | Eli Lilly and Company (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11207384-B2 | Rapid-acting insulin compositions | ELI LILLY AND COMPANY (US) | 2021-12-28 | — | — | US | disclosed |
| US-11123406-B2 | Rapid-acting insulin compositions | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| US-20160235693-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2016-08-18 | — | — | US | disclosed |
| WO-2016100042-A1 | RAPID-ACTING INSULIN COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160166695-A1 | RAPID-ACTING INSULIN COMPOSITIONS | ELI LILLY AND COMPANY | 2016-06-16 | — | — | US | disclosed |
| US-20160129087-A1 | RAPID-ACTING INSULIN COMPOSITIONS | LILLY CO ELI (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2015171484-A1 | RAPID-ACTING INSULIN COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| US-20150231123-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2015-08-20 | — | — | US | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | PHARMACIA CORPORATION (US) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238382-A1 | URI Agonist/Vasodilator | GPR119, INSR, IAPP | NPY2R 147/4885NPY1R 85/4885NPY4R 116/4885 |
| US-20160166695-A1 | RAPID-ACTING INSULIN COMPOSITIONS | INSR, IAPP, GPR119 | NPY2R 574/4885NPY1R 253/4885NPY4R 176/4885 |
| US-20160129087-A1 | RAPID-ACTING INSULIN COMPOSITIONS | INSR, IAPP, GPR119 | NPY2R 461/4885NPY1R 183/4885NPY4R 227/4885 |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | NR3C2, REN, AGTR1 | NPY2R 630/4885NPY1R 861/4885NPY4R 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.